Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Merger or Acquisition (August 2020)
13 slides from Bionano Genomics's merger presentation, Aug 24, 2020
Slide 1: Creating a leader in digital cytogenetics
+ Erik Holmlin, PhD, CEO of Bionano GenomicsAugust 24, 2020 Creating a leader in digital cytogenetics through a combination of systems & consumables with Laboratory Developed Tests (LDTs) & services in a CLIA-certified setting
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimat
Slide 3: Bionano Sells the Saphyr System to Detect Structural Variations
Bionano Sells the Saphyr System to Detect the Other Genome Variant: Structural Variations (SVs)
Slide 4: Saphyr May Drive the Digital Cytogenetics Revolution
Uses combination of multiple techniques incl. microscopes to manually visualize banding patterns on intact chromosomes to detect SVs Saphyr May Drive the Digital Cytogenetics Revolution Uses Saphyr to automatically image 1000x more label patterns on single DNA molecules in massively parallel nanocha
Slide 5: Lineagen is a Complementary Business Providing Actionable Diagnostic Information
Lineagen is a Complementary Business that Provides Actionable Information through Diagnostic Services to Patients with Developmental Disorders FROM ONE BUCCAL SWAB . . . Five tests providing multiple revenue streamsCLIA-certified LDTs and servicesPersonalized, easy-to-understand resultsGenetic couns
Slide 6: More than Products: Lineagen is an Accelerant for Digital Cytogenetics
More than Products: Lineagen is an Accelerant for Digital Cytogenetics ESSENTIAL COMPONENTS FOR BUILDING REIMBURSED DX MENU ON SAPHYR Trained billing specialists lay groundwork for reimbursement of Saphyr LDTs COMBINING PRODUCT-AND SERVICE-BASED BUSINESSES Proprietary database from Toronto Sick Kids
Slide 7: Bionano + Lineagen Side-by-Side
Saphyr genome imaging system and consumables sold to leading scientists and clinicians for digital cytogeneticsAddresses a $2.6-3.8B market opportunity with system placement opportunity of ~10,000 systemsAdoption by leading cytogenetics labs in US and EuropeGrowing bibliography of publications valid
Slide 8: Bionano + Lineagen As One
Bionano + Lineagen As One:Topline Expansion, Bigger Addressable Market, Deeper Market Penetration & New Products as Bionano Expands Clinical Applications MULTIPLE WAYS TO ACCELERATE CLINICAL ADOPTION Existing Bionano Business Existing Lineagen Business First-Line CMA tests + WES + Expand to more ser
Slide 9: The Combination Drives Financial Benefits
The Combination Drives Financial Benefits REVENUE SYNERGIES Rapid market expansion for Saphyr Expand Lineagen testing to new markets Proprietary Cytogenetics IVD development Operating Expenses Lineagen provides BNGO with a strategic platform in the form of CLIA-certification and an existing commerci
Slide 10: Combining A Genomics Platform Company With A Diagnostic Testing Company Has Been Done Before
Combining A Genomics Platform Company With A Diagnostic Testing Company Has Been Done Before 2013 2020 + Illumina Verinata Health Invitae Archer +
Slide 11: 2019 Pro Forma Financial Snapshot
2019 Pro Forma Financial Snapshot ($ in millions) Revenue Cost of Revenue LineagenStandalone BNGOStandalone $10.1M $6.8M $7.5M $3.4M BNGO+LineagenPro forma $17.6M $10.2M 2019
Slide 12: Summary Terms
Summary Terms ($ in millions) Bionano acquired Lineagen by way of a stock deal valued at approximately$9.6M plus repayment of Lineagen’s $1.1M PPP loan Consideration Cash: None Stock: ~6.2M (based on pps of $0.81) $5M Shares: Value: Liabilities: $4.6M in trade payables assumed1 + $1.1M PPP loan repa
Slide 13: Creating a leader in digital cytogenetics
Creating a leader in digital cytogenetics through a combination of systems & consumables with Laboratory Developed Tests (LDTs) & services in a CLIA-certified setting + Erik Holmlin, PhD, CEO of Bionano GenomicsAugust 24, 2020
Bionano Genomics — Merger or Acquisition (August 2020) on 6ix